Trending...
- From Speech Therapy to 300+ Episodes: Brother Marcus Turns His Voice Into a Movement Launching a 24/7 Inspiration Radio Network on Day 100 of the Year
- Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence
- L2 Aviation Appoints Tony Bailey as President and Chief Operating Officer
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Atos SE ("Atos" or the "Company") (OTC: AEXAY) investors concerning the Company and its officers' possible violations of federal securities laws.
On April 1, 2021, Atos issued a press release revealing that its auditors issued a "qualified opinion . . . as to two US legal entities representing 11% of 2020 consolidated revenue that require additional diligences." Specifically, the auditors identified "internal weaknesses over financial reporting process and revenue recognition in accordance with IFRS 15 leading to several accounting errors, as well as risk of override of controls in this respect." The Company stated that it had hired external firms to conduct an investigation and that, due to those procedures, the auditors had not been able to obtain sufficient evidence that the Company's financial statements were free of material misstatements within the necessary timeframe.
More on The PennZone
On this news, the Company's share price fell $1.67 per share, or 10.81%, to close at $13.78 per share on April 1, 2021, thereby injuring investors.
If you purchased Atos securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
On April 1, 2021, Atos issued a press release revealing that its auditors issued a "qualified opinion . . . as to two US legal entities representing 11% of 2020 consolidated revenue that require additional diligences." Specifically, the auditors identified "internal weaknesses over financial reporting process and revenue recognition in accordance with IFRS 15 leading to several accounting errors, as well as risk of override of controls in this respect." The Company stated that it had hired external firms to conduct an investigation and that, due to those procedures, the auditors had not been able to obtain sufficient evidence that the Company's financial statements were free of material misstatements within the necessary timeframe.
More on The PennZone
- Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
- EduCare Inc. Bridges Critical Gap in Breast Cancer Education with Spanish COPE Library Launch
- Engineering leaders from industry, academia to gather at IISE Annual Conference & Expo in Arlington, Texas
- AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
- BestDoc Launches AI Call Center for Healthcare
On this news, the Company's share price fell $1.67 per share, or 10.81%, to close at $13.78 per share on April 1, 2021, thereby injuring investors.
If you purchased Atos securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- Giftella Launches AI Gift-Finder App That Replaces Guesswork With Personalized Picks in Seconds
- Beverly.io Announces Nationwide Expansion and Poppins Payroll Partnership for Families
- Collectors gathered 'round the playing circle to compete for the rarest and best examples at Morphy's April 11 Premier Marbles auction
- New Book: The Battle for Truth and Shadows - Guardians of Light - Epic Fantasy Unveils a War Between Light and Deception
- Clash of Prompts: The World's First AI Prompt Battle Royale
- $7.6 Billion US Crypto ATM Market by 2034; California and Texas Crypto ATM Deployments for Bitcoin Bancorp (Stock Symbol: BCBC); 1000 Kiosk Inventory
- MainConcept Announces Multiview Encoding for Apple Immersive Video
- CCHR Rejects Global Psychiatric Push to Electroshock Children
- iVAM2-ST2110 to Simplify IP Transitions and Reduce Monitoring Complexity
- Americans Leave Behind or Discard 42% of Their Belongings When Moving Out for the First Time, Talker Research Finds
- Central Florida Luxury Real Estate Firm DANHOLM COLLECTION Partners with Luxury Presence to Expand Global Buyer Reach
- Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
- RemodelCalculators.com Launches 15 Free Home Renovation Tools
- InterMountain Management Announces the Re-opening of Holiday Inn Express & Suites Alexandria
- CB Stuffer Expands New England Footprint with Launch at Common Man Roadside in Hooksett, NH
- Contracting Resources Group Named to the 2026 Inc. Regionals: Mid-Atlantic List
- Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
- Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
- New Bethany Hosted "Food is Medicine" Roundtable with Community Leaders on April 1
- Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL